» Articles » PMID: 17978033

Opioid-mediated Placebo Responses Boost Pain Endurance and Physical Performance: is It Doping in Sport Competitions?

Overview
Journal J Neurosci
Specialty Neurology
Date 2007 Nov 6
PMID 17978033
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

The neurobiological investigation of the placebo effect has shown that placebos can activate the endogenous opioid systems in some conditions. So far, the impact of this finding has been within the context of the clinical setting. Here we present an experiment that simulates a sport competition, a situation in which opioids are considered to be illegal drugs. After repeated administrations of morphine in the precompetition training phase, its replacement with a placebo on the day of competition induced an opioid-mediated increase of pain endurance and physical performance, although no illegal drug was administered. The placebo analgesic responses were obtained after two morphine administrations that were separated as long as 1 week from each other. These long time intervals indicate that the pharmacological conditioning procedure has long-lasting effects and that opioid-mediated placebo responses may have practical implications and applications. For example, in the context of the present sport simulation, athletes can be preconditioned with morphine and then a placebo can be given just before competition, thus avoiding administration of the illegal drug on the competition day. However, these morphine-like effects of placebos raise the important question whether opioid-mediated placebo responses are ethically acceptable in sport competitions or whether they have to be considered a doping procedure in all respects.

Citing Articles

Top-down control of the descending pain modulatory system drives placebo analgesia.

Livrizzi G, Liao J, Johnson D, Lubejko S, Chang-Weinberg J, Dong C bioRxiv. 2025; .

PMID: 39990412 PMC: 11844511. DOI: 10.1101/2025.02.13.638185.


An update on non-pharmacological interventions for pain relief.

Wang Y, Aaron R, Attal N, Colloca L Cell Rep Med. 2025; 6(2):101940.

PMID: 39970872 PMC: 11866493. DOI: 10.1016/j.xcrm.2025.101940.


Placebo and nocebo interventions impact perceived but not actual proprioceptive accuracy.

Horvath A, Aranyosy B, Drozdovszky O, Szabo A, Koteles F PLoS One. 2024; 19(8):e0307072.

PMID: 39213316 PMC: 11364228. DOI: 10.1371/journal.pone.0307072.


Neuropsychological mechanisms of observational learning in human placebo effects.

Raghuraman N, White J, Watson L, Bellei-Rodriguez C, Shafir R, Wang Y Psychopharmacology (Berl). 2024; .

PMID: 38743108 PMC: 11561162. DOI: 10.1007/s00213-024-06608-7.


Translating knowledge on placebo and nocebo effects into clinical practice.

Caliskan E, Bingel U, Kunkel A Pain Rep. 2024; 9(2):e1142.

PMID: 38533458 PMC: 10965200. DOI: 10.1097/PR9.0000000000001142.


References
1.
Pacheco-Lopez G, Engler H, Niemi M, Schedlowski M . Expectations and associations that heal: Immunomodulatory placebo effects and its neurobiology. Brain Behav Immun. 2006; 20(5):430-46. DOI: 10.1016/j.bbi.2006.05.003. View

2.
Benedetti F, Mayberg H, Wager T, Stohler C, Zubieta J . Neurobiological mechanisms of the placebo effect. J Neurosci. 2005; 25(45):10390-402. PMC: 6725834. DOI: 10.1523/JNEUROSCI.3458-05.2005. View

3.
Wager T, Rilling J, Smith E, Sokolik A, Casey K, Davidson R . Placebo-induced changes in FMRI in the anticipation and experience of pain. Science. 2004; 303(5661):1162-7. DOI: 10.1126/science.1093065. View

4.
Wager T, Scott D, Zubieta J . Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci U S A. 2007; 104(26):11056-61. PMC: 1894566. DOI: 10.1073/pnas.0702413104. View

5.
Petrovic P, Kalso E, Petersson K, Ingvar M . Placebo and opioid analgesia-- imaging a shared neuronal network. Science. 2002; 295(5560):1737-40. DOI: 10.1126/science.1067176. View